The site offers API process development and manufacturing for oligonucleotides, peptides & conjugates from preclinical to commercial manufacturing.
The 74-acre campus offers a unique one-site solution for oligonucleotides, peptides, and related synthetic conjugates with approximately 30 oligonucleotide manufacturing lines at various scales and over 20 peptide production lines. When combining the peptide capacity in our Taixing site, the total reactor volume of solid-phase peptide synthesizers at WuXi TIDES has reached over 41,000 L.
We have recently opened our new R&D Center in Changzhou, significantly expanding our capabilities in developing advanced therapies covering small molecules, oligonucleotides, and peptides as well as complex synthetic conjugates. Strategically located just 15 minutes from our existing Changzhou API manufacturing site, the R&D Center is designed with six R&D buildings. Upon full operation, the Center will accommodate approximately 3,000+ scientists with 170+ specialized laboratories. The first operational building, dedicated to API development for oligonucleotides, peptides, and complex synthetic conjugates, spans over 160,000 square feet. The modular lab integrates essential workflows with latest digitalization and automation controls to achieve faster data turnaround and higher efficiency.
Our Changzhou site has successfully passed numerous inspections by the US FDA, China NMPA, Japan PMDA, South Korea MFDS, and Brazil ANVISA. More specifically, the site recently passed a PAI for a new peptide drug from Japan PMDA.
